Publicaciones - IR Sant Pau

Buscar

01/06/2025 Assessment of patient-reported outcomes from the phase 3 vivacity-MG3 study of nipocalimab in gMG

Vicente, EC, Pease, S, Imran, N, Gandhi, K, Ait-Tihuaty, M, Turkoz, I, Coteur, G, Gary, C, Choudhry, Z, Ramchandran, S, Vissing, J. Assessment of patient-reported outcomes from the phase 3 vivacity-MG3 study of nipocalimab in gMG. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Herding-like behaviour in myasthenia gravis treatment decisions: exploring underlying mechanisms

Villaverde, R, Gomez-Ballesteros, R, Reyes, V, Armangue, T, Querol, L, Gutierrez-Gutierrez, G, Sotoca, J, Ares, A, Salas, E, Abos, PD, Squaglia, A, Maurino, J, Cortes-Vicente, E. Herding-like behaviour in myasthenia gravis treatment decisions: exploring underlying mechanisms. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: SELECTED SECONDARY OUTCOMES FROM THE ADHERE TRIAL

Lewis, RA, Suresh, N, Mazzeo, A, Allen, JA, Querol, L, Hussain, YM, Gwathmey, KG, Guptill, JT, Istas, G, Van Hoorick, B, Mole, T, Kuwabara, S, Basta, I, van Door, PA. SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: SELECTED SECONDARY OUTCOMES FROM THE ADHERE TRIAL. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

01/06/2025 EFFICACY OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: PHASE 2 SUBGROUP ANALYSES

Lewis, RA, Querol, L, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. EFFICACY OF RILIPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: PHASE 2 SUBGROUP ANALYSES. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

01/06/2025 SAFETY AND EFFICACY OF RILIPRUBART IN CIDP 76-WEEK PHASE 2 TRIAL RESULTS

Falzone, Y, Querol, L, Lewis, R, Hartung, HP, van Doorn, P, Lin, J, Donnie, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, R. SAFETY AND EFFICACY OF RILIPRUBART IN CIDP 76-WEEK PHASE 2 TRIAL RESULTS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

01/06/2025 CHAT-GPT-4O IN DIAGNOSIS AND MANAGEMENT OF REAL-LIFE POLYNEUROPATHY CASES: COMPARATIVE ANALYSIS WITH NEUROLOGISTS

De Lorenzo, A, Moretti, GS, Bertini, A, De Lorenzo, A, Vidiella, RC, Falzone, YM, Fortanier, E, Gendre, T, Gentile, F, Hadden, R, Islam, B, Kleopa, K, Cejas, LL, Leonardi, L, Mandia, D, Marion, M, Mira, V, Peric, S, Querol, L, Rajabally, Y, Sevilla, T, Tomaselli, PJ, Tozza, S, Bosca, M, Brouwer, M, Cocco, A, Cousyn, L, De Santis, T, Gonzalez, F, Lukic, MJ, Mistry, N, Maranzano, A, Morena, E, Nakano, FN, Saura, GO, Sechi, E, Ticozzi, N, Troisi, S, Tsokkos, T, Aymeric, W, Pisciotta, C, Orazio, EN, Pareyson, D, Doneddu, PE. CHAT-GPT-4O IN DIAGNOSIS AND MANAGEMENT OF REAL-LIFE POLYNEUROPATHY CASES: COMPARATIVE ANALYSIS WITH NEUROLOGISTS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

01/06/2025 EFFECT OF RITUXIMAB ON NEUROFILAMENT IN CIDP: DATA FROM THE CIDPRIT RANDOMIZED CONTROLLED TRIAL

Gallo, C, Doneddu, PE, Collet-Vidiella, R, Cocito, D, Manganelli, F, Falzone, Y, Pinter, GL, Benedetti, L, Mazzeo, A, Peci, E, Spina, E, Strano, C, Dalla Bella, E, Germano, F, Gentile, L, Liberatore, G, Cutellè, C, Bianchi, E, Querol, L, Nobile-Orazio, E. EFFECT OF RITUXIMAB ON NEUROFILAMENT IN CIDP: DATA FROM THE CIDPRIT RANDOMIZED CONTROLLED TRIAL. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

01/06/2025 EFFICACY AND SAFETY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS

Allen, JA, Door, PAV, Benedetti, L, Basta, I, Dysgaard, T, Eggers, C, Guptill, JT, Gwathmey, KG, Hewamadduma, C, Hofman, E, Hussain, YM, Kuwabara, S, Le Masson, G, Leypoldt, F, Lin, J, Lipowska, M, Lowe, M, Pinter, GL, Querol, L, Simu, MA, Chang, TN, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA. EFFICACY AND SAFETY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30DOI:. PMID:. IF:3.200(Q2/4D).

20/12/2021 Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome

Storm, CS, Kia, DA, Almramhi, MM, Bandres-Ciga, S, Finan, C, Hingorani, AD, Wood, NW, Clarimón, J., Dols-Icardo O., Kulisevsky J., Marín J., Pagonabarraga J., Lynch, Timothy L.. Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. Nature Communications. 2021; 12(1)DOI:10.1038/s41467-021-26280-1. PMID:34930919. IF:17.694(Q1/1D).

01/07/2021 Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease

Blauwendraat, C, Iwaki, H, Makarious, MB, Bandres-Ciga, S, Leonard, HL, Grenn, FP, Lake, J, Krohn, L, Tan, M, Kim, JJ, Gibbs, JR, Hernandez, DG, Ruskey, JA, Pihlstrom, L, Toft, M, van Hilten, JJ, Marinus, J, Schulte, C, Brockmann, K, Sharma, M, Siitonen, A, Majamaa, K, Eerola-Rautio, J, Tienari, PJ, Grosset, DG, Lesage, S, Corvol, JC, Brice, A, Wood, N, Hardy, J, Gan-Or, Z, Heutink, P, Gasser, T, Morris, HR, Noyce, AJ, Nalls, MA, Singleton, AB, Clarimón J., Dols-Icardo, O, Kulisevsky J., Pagonabarraga, J, Int Parkinsons Dis Genomics Consor. Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. ANNALS OF NEUROLOGY. 2021; 90(1)DOI:10.1002/ana.26090. PMID:33901317. IF:11.274(Q1/1D).

01/01/2024 Long-Term Results of Cortical Motor Stimulation for Neuropathic Peripheral and Central Pain: Real-World Evidence From Two Independent Centers.

Aibar-Durán JÁ, Villalba Martínez G, Freixer-Palau B, Araus-Galdós E, Morollón Sanchez-Mateos N, Belvis Nieto R, Revuelta Rizo M, Molet Teixeido J, García Sánchez C, de Quintana Schmidt C, Muñoz Hernandez F, Rodríguez Rodríguez R. Long-Term Results of Cortical Motor Stimulation for Neuropathic Peripheral and Central Pain: Real-World Evidence From Two Independent Centers.. Neurosurgery. 2024; 94(1)DOI:10.1227/neu.0000000000002638. PMID:37638720. IF:3.900(Q1/1D).

15/10/2023 SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.

Kulisevsky J, Esquivel A, Freire-Álvarez E, Gómez-Esteban JC, Legarda-Ramírez I, Mata-Álvarez-Santullano M. SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.. REVISTA DE NEUROLOGIA. 2023; 77(s02)DOI:10.33588/rn.77s02.2023217. PMID:37752685. IF:0.800(Q4/9D).

01/01/2023 The success of assessing cortical microstructure through surface-based diffusion-weighted neuroimaging.

Sampedro F. The success of assessing cortical microstructure through surface-based diffusion-weighted neuroimaging.. CLINICAL NEUROLOGY AND NEUROSURGERY. 2023; 234DOI:10.1016/j.clineuro.2023.107990. PMID:37806052. IF:1.800(Q2/5D).

01/03/2026 Motor fluctuations in Parkinson's disease leave a distinct immune fingerprint in blood

Pérez-González, R, Vázquez-Oliver, A, Rivas-Asensio, E, Campolongo, A, Pons-Pons, G, Martínez-Horta, S, Pagonabarraga, J, Pascual-Sedano, B, Kulisevsky, J. Motor fluctuations in Parkinson's disease leave a distinct immune fingerprint in blood. PARKINSONISM & RELATED DISORDERS. 2026; 144DOI:10.1016/j.parkreldis.2026.108208. PMID:41643584. IF:3.400(Q2/3D).

25/01/2026 Effects of immersive virtual reality and adaptive cognitive training on cognition and function in parkinson's disease mild cognitive impairment: a randomized clinical trial

Puig-Davi, A, Moreu-Valls, A, Aracil-Bolaños, I, Fernandez-Cocaño, A, Rodríguez-Antigüedad, J, Kulisevsky, G, Horta-Barba, A, Pagonabarraga, J, Kulisevsky, J, Martinez-Horta, S. Effects of immersive virtual reality and adaptive cognitive training on cognition and function in parkinson's disease mild cognitive impairment: a randomized clinical trial. Scientific Reports. 2026; 16(1)DOI:10.1038/s41598-025-31833-1. PMID:41582160. IF:3.900(Q1/2D).

15/01/2026 Hereditary Ataxias: From Pathogenesis and Clinical Features to Neuroimaging, Fluid, and Digital Biomarkers-A Scoping Review

Bernardi, E, López-Lombardía, O, Olmedo-Saura, G, Pagonabarraga, J, Kulisevsky, J, Pérez-Pérez, J. Hereditary Ataxias: From Pathogenesis and Clinical Features to Neuroimaging, Fluid, and Digital Biomarkers-A Scoping Review. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2026; 27(2)DOI:10.3390/ijms27020881. PMID:41596528. IF:4.900(Q1/3D).

15/12/2025 Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations

Ferreira, JJ, Stocchi, F, Antonini, A, Rascol, O, Ebersbach, G, Kulisevsky, J, Fonseca, MM, Ramos, D, Rocha, JF, Brigas, HC, Holenz, J, Poewe, W. Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations. Frontiers in Neurology. 2025; 16DOI:10.3389/fneur.2025.1715748. PMID:41473225. IF:2.800(Q2/5D).

10/12/2025 Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson's disease patients

Camacho-Meño, L, Labandeira, CM, Bravo, SB, Torres, MV, Bejr-Kasem, H, Molina-Crespo, A, Atienza, M, Lanciego, JL, Cantero, JL, Kulisevsky, J, Labandeira-Garcia, JL, Rodriguez-Perez, AI. Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson's disease patients. npj Parkinsons Disease. 2025; 12(1)DOI:10.1038/s41531-025-01230-6. PMID:41366251. IF:8.200(Q1/1D).

01/11/2025 Pharmacogenetics in advanced Parkinson's disease

Kulisevsky, J, García-Ruíz, P, Outeiro, TF, Gurevich, T, Klivènyi, P, Van Laar, T, Milanov, I, Pirker, W, Popescu, BO, Toft, M, Szász, JA. Pharmacogenetics in advanced Parkinson's disease. JOURNAL OF NEURAL TRANSMISSION. 2025; 132(11)DOI:10.1007/s00702-025-03057-0. PMID:41222708. IF:4.000(Q1/2D).

01/11/2025 Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients

Garcia-Forn, M, Castany-Pladevall, C, Creus-Muncunill, J, Golbano, A, Escaramís, G, Pérez-Pérez, J, Balantzategi, U, Hernan-Godoy, M, Brito, V, Kulisevsky, J, Martí, E, Pérez-Navarro, E. Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients. Neurotherapeutics. 2025; 22(6)DOI:10.1016/j.neurot.2025.e00716. PMID:40774881. IF:6.900(Q1/1D).

01/07/2025 A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC

García-González, P, Lara, HR, Compta, Y, Fernandez, M, van der Lee, SJ, de Rojas, I, Saiz, L, Painous, C, Camara, A, Muñoz, E, Marti, MJ, Valldeoriola, F, Puerta, R, Illán-Gala, I, Pagonabarraga, J, Dols-Icardo, O, Kulisevsky, J, Fortea, J, Lleó, A, Olivé, C, de Boer, SCM, Hulsman, M, Pijnenburg, YAL, Belloso, RD, Muñoz-Delgado, L, Rueda, DB, Gómez-Garre, P, Aldecoa, I, Aragonés, G, Vara, JH, Mendioroz, M, Pérez-Tur, J, Visser, PJ, den Braber, A, Papma, JM, Montes, AM, Rodriguez-Rodriguez, E, Blázquez-Folch, J, Miguel, A, García-Gutiérrez, F, Cano, A, Valero, S, Marquié, M, Capdevila-Bayo, M, Rosende-Roca, M, Quintela, I, Carracedo, A, Tàrraga, L, Real, LM, Royo, JL, Erro, ME, Guerrero, C, Torres, DC, Blázquez-Estrada, M, San Millán, B, Teijeira, S, Rolan, DV, Hernández, I, Sánchez-Soblechero, A, de la Casa-Fages, B, López, SS, Baviera-Muñoz, R, Lavín, A, Taipa, R, Amer, G, Martinez-Saez, E, Fernández-Matarrubia, M, Lage-Martínez, C, Alvarez, V, Molina-Porcel, L, Holstege, H, Mir, P, Belbin, O, Boada, M, Fernández, V, Bullido, MJ, Rábano, A, Sánchez-Juan, P, Ruiz, A. A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC. EUROPEAN JOURNAL OF HUMAN GENETICS. 2025; 33(7)DOI:10.1038/s41431-025-01872-3. PMID:40379966. IF:4.600(Q1/2D).

01/06/2025 Clinical spectrum of anti-IgLON5 disease: A case series with three distinct movement disorder phenotypes

Alberti-Vall, B, Olmedo-Saura, G, Domine, M, Borrell-Pichot, M, Avila, MC, Jordana, AV, Pagonabarraga-Mora, J, Kulisevsky, J, Perez, P. Clinical spectrum of anti-IgLON5 disease: A case series with three distinct movement disorder phenotypes. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/05/2025 Cognitive and neuro-psychiatric profile in adult patients with epilepsy secondary to Tuberous Sclerosis Complex

Toscano-Prat, C, García-Sánchez, C, Ros-Castelló, V, Barguilla-Arribas, A, Saladich, IG, Rodríguez-Clifford, K, Torra-Balcells, R, Boronat, S, Sierra-Marcos, A. Cognitive and neuro-psychiatric profile in adult patients with epilepsy secondary to Tuberous Sclerosis Complex. EPILEPSY & BEHAVIOR. 2025; 166DOI:10.1016/j.yebeh.2025.110380. PMID:40101321. IF:2.300(Q2/4D).

26/04/2025 Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline (vol 272, 246, 2025)

Rodríguez-Antigüeedad, J, Martínez-Horta, S, Puig-Davi, A, Horta-Barba, A, Pagonabarraga, J, Fonticoba, TD, Jesus, S, Cosgaya, M, Caldentey, JG, Avila-Rivera, MA, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Mayordomo, VG, Ardura, JG, García-Soto, JD, Borrué, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Mendoza, Z, Pareés, I, Alonso, PS, Losada, MGA, Ariztegui, NL, Gastón, I, Martínez, JR, Buongiorno, MT, Ordas, C, Valero, C, Puente, V, Kurtis, M, Estrada, MB, Martínez-Martín, P, Mir, P, Santos-García, D, Kulisevsky, J. Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline (vol 272, 246, 2025). JOURNAL OF NEUROLOGY. 2025; 272(5)DOI:10.1007/s00415-025-13077-1. PMID:40285930. IF:4.600(Q1/2D).

05/03/2025 Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline

Rodríguez-Antigüedad, J, Martinez-Horta, S, Puig-Davi, A, Horta-Barba, A, Pagonabarraga, J, Fonticoba, TD, Jesús, S, Cosgaya, M, Caldentey, JG, avila-Rivera, MA, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Mayordomo, VG, Ardura, JG, Garcia-Soto, JD, Borrue, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Mendoza, Z, Parees, I, Alonso, PS, Losada, MGA, Ariztegui, NL, Gaston, I, Martinez, JR, Buongiorno, MT, Ordas, C, Valero, C, Puente, V, Kurtis, M, Estrada, MB, Martínez-Martín, P, Mir, P, Santos-García, D, Kulisevsky, J. Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline. JOURNAL OF NEUROLOGY. 2025; 272(3)DOI:10.1007/s00415-024-12808-0. PMID:40042541. IF:4.600(Q1/2D).

08/01/2026 Pain Hypersensitivity in a Mouse Model of Marfan Syndrome

Kordikowski, R, Coutinho, J, Martínez-Martel, I, Penas, C, Martín-Mur, B, Pérez, B, Jiménez-Altayó, F, Pol, O. Pain Hypersensitivity in a Mouse Model of Marfan Syndrome. Antioxidants. 2026; 15(1)DOI:10.3390/antiox15010080. PMID:41596139. IF:6.600(Q1/1D).

18/12/2025 Hydrogen-Rich Water Potentiates Cannabinoid- and Gabapentinoid-Induced Analgesia in Neuropathic Pain

Tort, NA, Negrini-Ferrari, SE, Pol, O. Hydrogen-Rich Water Potentiates Cannabinoid- and Gabapentinoid-Induced Analgesia in Neuropathic Pain. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025; 26(24)DOI:10.3390/ijms262412155. PMID:41465581. IF:4.900(Q1/3D).

01/06/2025 Fast-track strategy to shorten hospital stay in acute complicated paediatric appendicitis: protocol of the FTAA clinical trial

Leganes, C, Zapata, MJM, Valle, JM, Membrilla, E, Bordon, EA, Palazón, P, Fortes, LM, Núñez, B, Alvarez, N, Pueyo, C, Soria, A, Oviedo, M, Delgado-Espinoza, CE, Antonijoan, RM. Fast-track strategy to shorten hospital stay in acute complicated paediatric appendicitis: protocol of the FTAA clinical trial. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).

01/06/2025 Non-commercial sponsored clinical trials with medicinal products in Spain since CTIS implementation

Delgado-Espinoza, CE, Garcia, CP, Hosey, KA, Pestana, MJC, Lasso, LFC, Arbos, RMA. Non-commercial sponsored clinical trials with medicinal products in Spain since CTIS implementation. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).

01/06/2025 Environmental impact of avoidable tertiary care: earth-caring arguments for decentralizing trials

Pontes, C, Cortes, M, Delgado, CE, Castillo, LF, Amaro, K, Torres, F, Antonijoan, RM. Environmental impact of avoidable tertiary care: earth-caring arguments for decentralizing trials. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).

01/06/2025 Needle in the haystack: searching for relevance in systematic screening of adverse drug reactions

Pestana, MC, Lasso, LFC, Hosey, KCA, Espinoza, CED, Garcia, CP, Arbos, RMA. Needle in the haystack: searching for relevance in systematic screening of adverse drug reactions. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).

01/06/2025 Increasing use of gabapentinoids out of their authorised indications

Pontes, C, Cortés, M, de Pando, T, Gomez-Oliveros, B, Antonijoan, RM, Carot-Sans, G, Ramiro, M. Increasing use of gabapentinoids out of their authorised indications. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).

01/06/2025 Rising alarm on strong opioids in the elderly: a description of utilization and prescription characteristics

Navarro, TDP, Perez, AM, Carot-Sans, G, Martinez, LE, Belis, MV, Nadal, AM, Garcia, CP. Rising alarm on strong opioids in the elderly: a description of utilization and prescription characteristics. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025; 81(1)DOI:. PMID:. IF:2.700(Q2/5D).

01/07/2021 The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design

Bernardo, M, Amoretti, S, Cuesta, MJ, Parellada, M, Mezquida, G, Corripio I., Mico, Juan Antonio. The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. SPANISH JOURNAL OF PSYCHIATRY AND MENTAL HEALTH. 2021; 14(3)DOI:10.1016/j.rpsm.2020.07.004. PMID:33020032. IF:6.795(Q1/3D).

01/01/2024 Impact of Stress on Brain Morphology: Insights into Structural Biomarkers of Stress-related Disorders.

Cardoner N, Andero R, Cano M, Marin-Blasco I, Porta-Casteràs D, Serra-Blasco M, Via E, Vicent-Gil M, Portella M. Impact of Stress on Brain Morphology: Insights into Structural Biomarkers of Stress-related Disorders.. Current Neuropharmacology. 2024; 22(5)DOI:10.2174/1570159X21666230703091435. PMID:37403395. IF:5.300(Q1/2D).

01/04/2026 Insight and depressive symptoms in eating disorders: the mediating role of disorder-specific psychopathology

Gawron, LP, Portella, MJ, Pousa, E. Insight and depressive symptoms in eating disorders: the mediating role of disorder-specific psychopathology. PSYCHIATRY RESEARCH. 2026; 358DOI:10.1016/j.psychres.2026.116965. PMID:41610566. IF:3.900(Q1/2D).

01/02/2026 Psychotropic Drugs: A Practical Guide for Use in Dermatology

Carmona-Rocha, E, De Diego-Adeliño, J, Tribó, MJ, Puig, L. Psychotropic Drugs: A Practical Guide for Use in Dermatology. Actas Dermo-Sifiliograficas. 2026; 117(2)DOI:10.1016/j.ad.2025.104518. PMID:41352592. IF:(Q/D).

01/02/2026 Representation and outcomes of individuals with major depression in routine care who are ineligible for randomized controlled trials: a nationwide register-based study

Hamina, A, Pinzón-Espinosa, J, Taipale, H, Schneider-Thoma, J, Radua, J, Efthimiou, O, Cardoner, N, Correll, CU, Fusar-Poli, P, Mittendorfer-Rutz, E, Penninx, BWJH, Ruhe, HG, Tanskanen, A, Vinkers, CH, Leucht, S, Vieta, E, Cipriani, A, Tiihonen, J, Luykx, JJ. Representation and outcomes of individuals with major depression in routine care who are ineligible for randomized controlled trials: a nationwide register-based study. World Psychiatry. 2026; 25(1)DOI:10.1002/wps.70013. PMID:41536102. IF:65.800(Q1/1D).

01/01/2026 A Smartphone-Based Psychological Intervention for Nonsuicidal Self-Injury (Kalmer App): Protocol for a Multicenter Double-Blind Randomized Controlled Trial

Julià, A, Jaén, I, Giménez, MC, García-Palacios, A, Pascual, JC, Estévez, AS, Lara, A, Méndez, I, Romero, S, Puntí, J, Soler, J, Solé-Casals, J, López-Solà, M, Vega, D. A Smartphone-Based Psychological Intervention for Nonsuicidal Self-Injury (Kalmer App): Protocol for a Multicenter Double-Blind Randomized Controlled Trial. Jmir Research Protocols. 2026; 15DOI:10.2196/86413. PMID:41592792. IF:(Q/D).

01/01/2026 Exploring the nexus of cognition and insight in euthymic bipolar patients

Massons, C, Cobo, J, Navarra-Ventura, G, Vicent-Gil, M, Serra-Blasco, M, Jubert, A, Agut, M, Palao, DJ, Cardoner, N. Exploring the nexus of cognition and insight in euthymic bipolar patients. EUROPEAN JOURNAL OF PSYCHIATRY. 2026; 40(1)DOI:10.1016/j.ejpsy.2025.100336. PMID:. IF:1.500(Q3/7D).

01/01/2026 Sex differences in neurocognitive response to metacognitive training in first-episode psychosis: Implications for personalized interventions

Verdaguer-Rodríguez, M., Comas, J.O., López-Carrilero, R., Díaz-Cutraro, L., Espinosa, V., Ruiz-Delgado, I., Barrigón, M.L., Grasa, E., Pousa, E., González-Higueras, F., Cid, J., Lorente-Rovira, E., Barajas, A., Ochoa, S.. Sex differences in neurocognitive response to metacognitive training in first-episode psychosis: Implications for personalized interventions. Archives of Womens Mental Health. 2026; 29(1)DOI:10.1007/s00737-025-01637-3. PMID:41661387. IF:2.700(Q2/4D).

01/12/2025 Combining Life History Calendars and Ecological Momentary Assessment for Evaluating Everyday Stress and Its Impact on Mental Health in Healthy Adults: Longitudinal Study

Chavarría-Elizondo, P, Tortella-Feliu, M, Fortea, L, De la Peña-arteaga, V, Juaneda-Seguí, A, Martínez-Zalacaín, I, Vilajosana, E, Radua, J, Shackman, AJ, Soriano-Mas, C, Fullana, MA. Combining Life History Calendars and Ecological Momentary Assessment for Evaluating Everyday Stress and Its Impact on Mental Health in Healthy Adults: Longitudinal Study. STRESS AND HEALTH. 2025; 41(6)DOI:10.1002/smi.70128. PMID:41307189. IF:2.700(Q2/4D).

01/09/2025 Impact of Relapse in BDNF Receptors Expression in Patients With a First Episode of Schizophrenia

Bioque, M, Llorca-Bofi, V, MacDowell, KS, Amoretti, S, Mezquida, G, Cuesta, MJ, Diaz-Caneja, CM, Ibáñez, A, Segarra, R, González-Pinto, A, Roldán, A, Sáiz, PA, Mané, A, Lobo, A, Martínez-Pinteño, A, Cano-Escalera, G, Berrocoso, E, Bernardo, M. Impact of Relapse in BDNF Receptors Expression in Patients With a First Episode of Schizophrenia. SCHIZOPHRENIA BULLETIN. 2025; 51(5)DOI:10.1093/schbul/sbaf012. PMID:39977257. IF:4.800(Q1/2D).

23/08/2025 Neural correlates of human fear conditioning and sources of variability in 2199 individuals

Radua, J, Savage, HS, Vilajosana, E, Jamieson, A, Abler, B, Åhs, F, Beckers, T, Cardoner, N, Cisler, JM, Diniz, JB, Bach, DR, Elsenbruch, S, Greening, SG, Holt, DJ, Kaczkurkin, AN, Keil, A, Kindt, M, Koch, K, LaBar, KS, Lam, CL, Larson, CL, Lonsdorf, TB, Merz, CJ, McLaughlin, KA, Neria, Y, Pine, DS, van Reekum, CM, Shackman, AJ, Soriano-Mas, C, Spoormaker, VI, Stout, DM, Straube, B, Straube, T, Tuominen, L, Visser, RM, Ahumada, L, Arolt, V, Batistuzzo, MC, Bazán, PR, Biggs, EE, Cano, M, Chavarría-Elizondo, P, Cooper, SE, Dannlowski, U, de la Peña-arteaga, V, Decross, SN, Domschke, K, Ehlers, MR, Graner, JL, Hamm, AO, Herrmann, MJ, Huggins, AA, Icenhour, A, Juaneda-Seguí, A, Junghoefer, M, Kircher, T, Koelkebeck, K, Kuhn, M, Labrenz, F, Lissek, SM, Lotze, M, Lueken, U, Margraf, J, Martínez-Zalacaín, I, Moeck, R, Morriss, J, Ortuño, M, Pittig, A, Porta-Casteras, D, Richter, J, Ridderbusch, IC, Rief, W, Roesmann, K, Rosén, J, Russmann, AN, Sjouwerman, R, Spohrs, J, Ströhle, A, Suarez-Jimenez, B, Ulrich, M, Wittchen, HU, Zhu, X, Waller, L, Walter, H, Thompson, PM, Bas-Hoogendam, JM, Groenewold, NA, Stein, DJ, van der Wee, NJ, Dunsmoor, JE, Marquand, AF, Harrison, BJ, Fullana, MA. Neural correlates of human fear conditioning and sources of variability in 2199 individuals. Nature Communications. 2025; 16(1)DOI:10.1038/s41467-025-63078-x. PMID:40849409. IF:15.700(Q1/1D).

19/08/2025 Mapping cross-modal functional connectivity of major neurotransmitter systems in the human brain

Saiz-Masvidal, C, De la Peña-Arteaga, V, Bertolín, S, Diez, I, Juaneda-Seguí, A, Martínez-Zalacaín, I, Chavarría-Elizondo, P, Subirà, M, Menchón, JM, Sepulcre, J, Fullana, MA, Soriano-Mas, C. Mapping cross-modal functional connectivity of major neurotransmitter systems in the human brain. Brain Structure & Function. 2025; 230(7)DOI:10.1007/s00429-025-02996-4. PMID:40828212. IF:2.900(Q1/1D).

01/08/2025 Effectiveness of a Post-discharge Phone-Based Smoking Cessation Intervention for Patients with Severe Mental Health Disorders: The 061 Quitmental Randomized Controlled Clinical Trial

Martinez, C, Feliu, A, Saura, J, Nieva, G, Pinet, C, Raich, A, Mondon, S, Barrio, P, Andreu, M, Hernández-Ribas, R, Costa, S, Suelves, JM, Vilaplana, J, Enriquez, M, Alaustre, L, Vilalta, E, Alvarez, JB, Guydish, J, Fernández, E, Ballbè, M. Effectiveness of a Post-discharge Phone-Based Smoking Cessation Intervention for Patients with Severe Mental Health Disorders: The 061 Quitmental Randomized Controlled Clinical Trial. International Journal of Mental Health and Addiction. 2025; 23(4)DOI:10.1007/s11469-024-01254-8. PMID:40936741. IF:2.500(Q2/4D).

01/03/2025 Interrelationships between polygenic risk scores, cognition, symptoms, and functioning in first-episode psychosis: A network analysis approach

Gil-Berrozpe, GJ, Segura, AG, Sánchez-Torres, AM, Amoretti, S, Giné-Servén, E, Vieta, E, Mezquida, G, Lobo, A, Gonzalez-Pinto, A, Andreu-Bernabeu, A, Roldán, A, Forte, MF, Castro, J, Bergé, D, Rodríguez, N, Ballesteros, A, Mas, S, Cuesta, MJ, Bernardo, M. Interrelationships between polygenic risk scores, cognition, symptoms, and functioning in first-episode psychosis: A network analysis approach. EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2025; 92DOI:10.1016/j.euroneuro.2024.12.002. PMID:39721378. IF:6.700(Q1/1D).

01/02/2025 Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial

Young, AH, Llorca, PM, Fagiolini, A, Falkai, P, Cardoner, N, Nielsen, RE, Blomqvist, O, Godinov, Y, Rive, B, Diels, J, Mulhern-Haughey, S, Reif, A. Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial. BRITISH JOURNAL OF PSYCHIATRY. 2025; 226(2)DOI:10.1192/bjp.2024.124. PMID:39618237. IF:7.600(Q1/1D).

01/03/2022 Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

Jansen, WJ, Janssen, O, Tijms, BM, Vos, SJB, Ossenkoppele, R, Visser, PJ, Alcolea D., Amyloid Biomarker Study Grp. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology. 2022; 79(3)DOI:10.1001/jamaneurol.2021.5216. PMID:35099509. IF:29.000(Q1/1D).

04/10/2023 Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning.

Neumann A, Ohlei O, Küçükali F, Bos IJ, Timsina J, Vos S, Prokopenko D, Tijms BM, Andreasson U, Blennow K, Vandenberghe R, Scheltens P, Teunissen CE, Engelborghs S, Frisoni GB, Blin O, Richardson JC, Bordet R, Lleó A, Alcolea D, Popp J, Marsh TW, Gorijala P, Clark C, Peyratout G, Martinez-Lage P, Tainta M, Dobson RJB, Legido-Quigley C, Van Broeckhoven C, Tanzi RE, Ten Kate M, Lill CM, Barkhof F, Cruchaga C, Lovestone S, Streffer J, Zetterberg H, Visser PJ, Sleegers K, Bertram L. Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning.. Genome Medicine. 2023; 15(1)DOI:10.1186/s13073-023-01233-z. PMID:37794492. IF:10.400(Q1/1D).

19/09/2023 Brain hypometabolism in non-demented microtubule-associated protein tau H1 carriers with Parkinson's disease.

Gasca-Salas C, Trompeta C, López-Aguirre M, Rodríguez Rojas R, Clarimon J, Dols-Icardo O, El Bounasri S, Guida P, Mata-Marín D, Hernández-Fernández F, Marras C, García-Cañamaque L, Plaza de Las Heras I, Obeso I, Vela L, Fernández-Rodríguez B. Brain hypometabolism in non-demented microtubule-associated protein tau H1 carriers with Parkinson's disease.. JOURNAL OF NEUROIMAGING. 2023; 33(6)DOI:10.1111/jon.13156. PMID:37726927. IF:2.300(Q2/5D).

13/09/2023 CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease.

Del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok-A-Hin YS, Lleó A, Alcolea D, van Nee M, Engelborghs S, van Alphen JL, Arezoumandan S, Chen-Plotkin A, Irwin DJ, van der Flier WM, Lemstra AW, Teunissen CE. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease.. Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-41122-y. PMID:37704597. IF:14.700(Q1/1D).

17/08/2023 Brain connectivity correlates of cognitive dispersion in a healthy middle-aged population: influence of subjective cognitive complaints.

Mulet-Pons L, Solé-Padullés C, Cabello-Toscano M, Abellaneda-Pérez K, Perellón-Alfonso R, Cattaneo G, Solana Sánchez J, Alviarez-Schulze V, Bargalló N, Tormos-Muñoz JM, Pascual-Leone A, Bartrés-Faz D, Vaqué-Alcázar L. Brain connectivity correlates of cognitive dispersion in a healthy middle-aged population: influence of subjective cognitive complaints.. JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES. 2023; 78(11)DOI:10.1093/geronb/gbad114. PMID:37587033. IF:4.800(Q1/1D).

01/06/2025 On the complexity of biomarker-driven diagnoses of Alzheimer's disease

Grasso, SM, Santos-Santos, MA, Clark, AL. On the complexity of biomarker-driven diagnoses of Alzheimer's disease. Journal of Neuropsychology. 2025; 19(2)DOI:10.1111/jnp.12428. PMID:40317662. IF:1.800(Q3/6D).

24/03/2025 Potential of facial biomarkers for Alzheimer's disease and obstructive sleep apnea in Down syndrome and general population

Echeverry-Quiceno, LM, Llambrich, S, Heredia-Lidón, A, Giménez, S, Rozalem-Aranha, M, Inampudi, P, Heuzé, Y, Sevillano, X, Fortea, J, Martinez-Abadias, N, Alzheimers Dis Neuroimaging Initiative. Potential of facial biomarkers for Alzheimer's disease and obstructive sleep apnea in Down syndrome and general population. FASEB JOURNAL. 2025; 39(6)DOI:10.1096/fj.202403009R. PMID:40123509. IF:4.200(Q1/2D).

01/03/2026 Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration

Garcia-Castro, J, Vandevrede, L, Donohue, MC, Vaqué-Alcázar, L, Rubio-Guerra, S, Selma-González, J, Heuer, HW, Morcillo-Nieto, AO, Franquesa, M, Dols-Icardo, O, Bejanin, A, Belbin, O, Fortea, J, Alcolea, D, Carmona-Iragui, M, Abdelnour, C, Barroeta, I, Santos-Santos, M, Saudinós, MBS, Sala, I, Lleó, A, Gorno-Tempini, ML, Mandelli, ML, Raman, R, Wills, AM, Barragan, E, Litvan, I, Boeve, B, Dickerson, B, Grossman, M, Huey, ED, Irwin, DJ, Pantelyat, A, Tartaglia, C, Rojas, JC, Boxer, AL, Illán-Gala, I. Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration. JPAD-Journal of Prevention of Alzheimers Disease. 2026; 13(3)DOI:10.1016/j.tjpad.2026.100486. PMID:41581260. IF:7.800(Q1/1D).

01/02/2026 Lessons from the Colombian kindred: rethinking Alzheimer's prevention

Fortea, J, Llibre-Guerra, J, O'Connor, A, Levin, J. Lessons from the Colombian kindred: rethinking Alzheimer's prevention. LANCET NEUROLOGY. 2026; 25(2)DOI:10.1016/S1474-4422(25)00481-8. PMID:41579884. IF:45.500(Q1/1D).

01/01/2026 Cerebrospinal Fluid Fatty Acids, Hypothalamic Inflammation, and Weight Loss in Human Obesity: A Longitudinal Study

Pané, A, Videla, L, Calvet-Mirabent, A, Castro-Barquero, S, Viaplana, J, Vaqué-Alcázar, L, Ibarzabal, A, Rozalem-Aranha, M, Bejanin, A, Moize, V, Vidal, J, De Hollanda, A, Ortega, E, Barroeta, I, Camacho, V, Chiva-Blanch, G, Fortea, J, Jiménez, A. Cerebrospinal Fluid Fatty Acids, Hypothalamic Inflammation, and Weight Loss in Human Obesity: A Longitudinal Study. DIABETES. 2026; 75(1)DOI:10.2337/db25-0595. PMID:41247745. IF:7.500(Q1/1D).

01/01/2026 Exploiting Generative Models for Downstream Classification Tasks on Latent Spaces Using 3D Brain MRI Scans: A Down Syndrome Case Study

Malé, J, Fortea, J, Rozalem-Aranha, M, Martínez-Abadías, N, Sevillano, X. Exploiting Generative Models for Downstream Classification Tasks on Latent Spaces Using 3D Brain MRI Scans: A Down Syndrome Case Study. Pattern Recognition And Image Analysis, Ibpria 2025, Pt Ii. 2026; 15938DOI:10.1007/978-3-031-99568-2_11. PMID:. IF:(Q/D).

12/12/2025 Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group

Ulugut, H, Younes, K, Montembeault, M, Bertoux, M, Irish, M, Kumfor, F, Fumagalli, GG, Samanci, B, Illán-Gala, I, Thompson, JC, Santillo, AF, Englund, E, Waldö, ML, Riedl, L, van den Stock, J, Vandenbulcke, M, Vandenberghe, R, Laforce, R, Ducharme, S, Pressman, PS, Caramelli, P, de Souza, LC, Takada, LT, Gurvit, H, Diehl-Schmid, J, Galimberti, D, Pasquier, F, Weintraub, S, Miller, BL, Sturm, VE, Whitwell, JL, Boeve, B, Rohrer, JD, Piguet, O, Gorno-Tempini, ML, Josephs, KA, Snowden, J, Rowe, JB, Warren, JD, Rankin, KP, Pijnenburg, YAL. Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group. Communications Medicine. 2025; 5(1)DOI:10.1038/s43856-025-01252-4. PMID:41387629. IF:(Q/D).